Innovative Collaboration for RNA Delivery Development
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a forward-thinking company focused on RNA delivery technology, has embarked on an exciting collaboration to enhance the delivery of circular RNA payloads. This strategic partnership involves evaluating Altamira's proprietary CycloPhore™ platform, envisioned for more effective delivery solutions in RNA drug development.
Understanding the CycloPhore Technology
The CycloPhore platform is designed for the safe and effective transmission of circular RNA (circRNA) into specific target cells. Utilizing advanced xPhore™ technology, it combines a unique 21-amino acid peptide enabling rapid self-assembly into functional nanoparticles. These nanoparticles exhibit specific size and charge properties, facilitating the avoidance of hepatic clearance, thereby broadening the range of target tissues accessible for delivery.
Advantages of Circular RNA Delivery
Circular RNA is emerging as a groundbreaking approach due to its potential benefits, including lower dosing requirements and more infrequent administrations compared to traditional linear mRNA approaches. This innovative method represents a shift toward more efficient and effective RNA drug delivery options.
Implications of the Collaboration
Under the terms of this agreement, Altamira and its partner will conduct both in vitro and in vivo tests to assess the functionality of these CycloPhore nanoparticles for circRNA delivery. Notably, the collaboration agreement provides the partner the opportunity to engage in licensing discussions regarding the developed circRNA nanoparticles alongside their proprietary RNA payloads.
Expert Insights from Altamira's Leadership
Commenting on the collaboration, Covadonga Pañeda, PhD, and Altamira's Chief Operating Officer, expressed enthusiasm for this initiative. She emphasized the company’s commitment to exploration and innovation, reinforcing CycloPhore's intended use for circular RNA, a promising avenue in RNA therapeutics development. The team eagerly anticipates collaborating with the new partner, recognized for their expertise in circular RNA and their vision for developing transformative therapeutic solutions.
About Altamira Therapeutics and Its Research Activities
Altamira Therapeutics stands at the forefront of peptide-based nanoparticle technology, dedicated to enhancing RNA delivery to tissues beyond the liver. The versatile xPhore™ platform accommodates various RNA types, including siRNA, mRNA, and circRNA, making it an attractive option for pharmaceutical and biotech companies. Altamira is advancing multiple proprietary flagship programs, focusing on significant medical needs, including treatments for KRAS-driven cancers and rheumatoid arthritis, both currently in preclinical development.
Investment in Future Therapeutics
Furthermore, Altamira holds a substantial stake in Altamira Medica AG, which features the commercial-stage asset Bentrio®, an over-the-counter nasal spray targeted at allergic rhinitis. Continuing its strategy for growth, Altamira is also investigating opportunities related to their inner ear legacy assets.
The Path Forward for Altamira
Since its inception in 2003, Altamira Therapeutics has been dedicated to advancing healthcare through innovative RNA delivery solutions. With headquarters in Hamilton, Bermuda, and operational centers in Basel, Switzerland, the company is well-positioned to continue its commitment to developing ground-breaking therapeutic solutions.
Frequently Asked Questions
What is the CycloPhore technology developed by Altamira?
CycloPhore is a platform designed for the effective delivery of circular RNA into targeted cells, utilizing advanced self-assembling nanoparticles for enhanced performance.
How does circular RNA delivery compare to traditional methods?
Circular RNA delivery can potentially offer benefits such as lower dosage requirements and reduced frequency of administration compared to linear RNA methods.
What is the main goal of Altamira's collaboration?
Altamira aims to evaluate the use of its CycloPhore platform for delivering circRNA payloads, with an option for the partner to negotiate licensing agreements for any innovations arising from the collaboration.
What is Altamira’s focus in drug development?
Altamira is focused on developing RNA delivery technologies targeting not only the liver but also other areas, addressing significant medical challenges through innovative solutions.
Where is Altamira Therapeutics headquartered?
Altamira Therapeutics is headquartered in Hamilton, Bermuda, with its main operational activities based in Basel, Switzerland.
